 |
2019 Investigation Report on China's Urokinase Market: Analysis Through 2013-2023 |  |
| Tuesday, 24. September 2019 13:22 |
|---|
|
Dublin, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Urokinase Market, 2019-2023" report has been added to ResearchAndMarkets.com's offering. Topics Covered
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important component of thrombus, current thrombolytic therapy mainly uses drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin. Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc. Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue. Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis. Economic development, aging population and an unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.6% by sales value and about 38.5% by sales volume. It is expected that the market size of Urokinase in China will continue to grow in the next few years. Key Topics Covered 1 Relevant Concepts of Urokinase 2 Sales of Urokinase in China, 2013-2017 3 Analysis of Major Urokinase Manufacturers in China, 2013-2017 4 Prices of Urokinase in China, 2017-2018 5 Prospect of China's Urokinase Market, 2019-2023 List of Charts
For more information about this report visit https://www.researchandmarkets.com/r/fxzhkw Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
|
| Related Links: |
| Author: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account. |
Real-time